{"id":"W3175514092","doi":"10.1016/j.jtocrr.2021.100205","title":"Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston General Hospital","funders":"Janssen Pharmaceuticals; Loxo Oncology; Chugai Pharmaceutical; Genentech; Free Market Institute, Texas Tech University; National Institutes of Health; Shire; Bayer Fund; Mirati Therapeutics; Clovis Oncology; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Verily Life Sciences; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; AbbVie; ACEA Biosciences; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Sanofi; EMD Serono; Mesothelioma Applied Research Foundation; Heron Therapeutics; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Pfizer; Boehringer Ingelheim; Amgen; Roche","keywords":"Pembrolizumab; Medicine; Brain metastasis; Internal medicine; Chemotherapy; Lung cancer; Oncology; Confidence interval; Metastasis; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00884251,0.00102782,0.003096439,0.001439743,0.0002212742,0.001255743,0.0006263324,0.0006502966,0.001154781],"category_scores_gemma":[0.005892787,0.0004826049,0.008593326,0.001848704,0.0002720654,0.0006683984,0.0007966001,0.0005162332,0.000167362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005180733,"about_ca_system_score_gemma":0.0004915168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008268152,"about_ca_topic_score_gemma":0.001325055,"domain_scores_codex":[0.9948153,0.002326135,0.0009993761,0.00113372,0.0005434309,0.000182052],"domain_scores_gemma":[0.9949741,0.001878694,0.002135825,0.0004520086,0.0003641626,0.0001951996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07299773,0.0001755557,0.5524677,0.005079383,0.3361805,0.0002093443,0.0001244673,0.002297739,0.003504378,0.0001257582,0.001032495,0.02580499],"study_design_scores_gemma":[0.006249066,0.008472857,0.7221637,0.0005807694,0.2537423,0.0006335286,0.0001778356,0.002386137,0.001662827,0.0003433237,0.003499231,0.00008839732],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9333875,0.05932011,0.001223488,0.0001232497,0.0000960318,0.0001590908,0.004788073,0.00002791967,0.0008746059],"genre_scores_gemma":[0.9931479,0.003189484,0.0003146227,0.00009399939,0.00006734549,0.0001239373,0.002907065,0.000008391467,0.0001471571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00884251,"threshold_uncertainty_score":0.04676425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04276317074613412,"score_gpt":0.4012464907436726,"score_spread":0.3584833199975385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}